NCT01828112
Clinical Trial Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT01828112 |
| Title | LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib |
| Recruitment | Completed |
| Gender | both |
| Phase | Phase III |
| Variant Requirements | Yes |
| Sponsors | Novartis Pharmaceuticals |
| Indications | |
| Therapies | |
| Age Groups: | adult |
| Covered Countries | USA | TUR | NLD | LBN | ITA | ISR | IRL | GBR | FRA | ESP | DEU | CHE | CAN | BEL |
CKB BOOST